about
Response Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 InfectionInterferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infectionIP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infectionIP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIVImproved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trialA proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosisHistamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidaseImpact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.Histamine: a novel approach to cancer immunotherapy.Adjuvant histamine in cancer immunotherapy.Alleviating oxidative stress in cancer immunotherapy: a role for histamine?Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionHistamine in cancer immunotherapy: a preclinical background.Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.Role of the ERK pathway for oxidant-induced parthanatos in human lymphocytes.Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemiaReactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia--background and results.Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.5-Propyl-2-deoxyuridine induced interference with glycosylation in herpes simplex virus infected cells. Nature of PdU-induced modifications of N-linked glycans.Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosisAddition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).Early results of a trial of the Oka-strain varicella vaccine in children with leukaemia or other malignancies in Sweden.TLR-Stimulated Neutrophils Instruct NK Cells To Trigger Dendritic Cell Maturation and Promote Adaptive T Cell Responses.Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.A cell-to-cell mediated interaction involving monocytes and non-T/CD16+ natural killer (NK) cells is required for histamine H2-receptor-mediated NK-cell activation.Leukocyte oxygen radical production determines disease severity in the recurrent Guillain-Barré syndrome.Absence of cytomegalovirus in high-coverage DNA sequencing of human glioblastoma multiforme.Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.Accumulation of natural killer cells after hepatic artery embolisation in the midgut carcinoid syndrome.Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.Association between interleukin-28B-related genetic variants and liver histopathology differs between hepatitis C virus genotypes.
P50
Q27481003-6CDCC55D-6953-4E14-A1BE-31D8654D4FA4Q28262594-33EEB271-4A58-4356-A0A3-A6DA9781165EQ28276247-5597555F-3FE8-4829-9F29-6D882B90D1A1Q28287283-178E7A4D-FE8C-4550-89C2-8AB839F07650Q28303488-2A84B36A-39AD-43B3-9E18-572DF93A818EQ28361854-FE8471F6-4007-468D-A428-AB717E61757FQ28392943-E325F92A-D587-4D80-92E4-4DBAF734D0B4Q28729225-03F7D25A-FC03-4F09-83DF-D3DC97F8C690Q33413296-A5377B13-2D94-4F66-A4EE-AC9EB5384B1FQ33842239-A0929217-5CB0-4C65-8AAE-A02BC1637C80Q33917156-EA17BA5E-BBEC-4376-86E3-7BA8EA90465EQ33963628-462ABD89-9E87-4968-AC93-D8D84D8625FFQ34103600-A784E6F2-84D3-49FF-AB92-54643B8AEDBFQ34129599-D8BC38AC-4D75-4EEF-B353-9AD0D9852EBFQ34599847-41BCC825-4930-4AF6-B1A7-BB85510D1F69Q34689415-0DB35ADC-CEE1-4AF1-9A41-C2429C64CC52Q34775684-E1CE7410-30DA-4526-8A1B-154853AAB7AFQ35107809-526EF61D-6E9A-411D-839A-67271EAD062DQ36597388-6B0408B5-D95D-45EA-A779-0F55D4E1483EQ36618933-D56238FB-357B-40FE-94AE-B5755F0024E3Q36946572-85F1522F-B012-40BE-9DB2-56F9F992CE5DQ37362596-1E24708F-487A-4124-B140-63673D0DBF49Q37409280-E8FD5046-9CED-4983-BFD3-E076E6FBE5ABQ37571981-7A9122D5-6AC4-4C77-A33B-B7EA6A00560FQ38322963-B46CBB2D-CC81-4687-93DF-98C17800E61EQ38772230-354F5D2F-F567-471F-A12B-D0BF144E642AQ39355305-AD2C2757-7561-4D53-8A45-078B4E6B50B3Q40465372-F6449F25-03A0-4735-A53E-C844A640FB5CQ40822096-21018358-2D9B-48C7-AD1F-B52CA69D4CDFQ40825087-411735CF-77E2-4DE3-97BB-5C26A4241D2FQ41527981-CC0718AF-EE42-4018-81D7-DC40A32EC5FCQ41736530-864A316E-BFDF-4764-941C-A0CBE4E3E0BBQ42135283-3964263F-00F7-48C5-BC93-E8E1A552852AQ42210297-15DFAD29-EE30-4572-937E-991A75B64F66Q42257750-CE17EDEA-6D4C-4FF3-A4AD-9FD479615782Q42271105-80D5B2E4-7306-45BC-BEB3-79C2A3952E69Q42590462-FF4D4FB6-682F-4C87-A047-F09ED8309BCDQ42683573-2A10DED8-F552-42EE-9773-9B2391DFA643Q42852367-08023085-C9ED-45FA-B7A0-6E993BF3C011Q42977071-B12E15B1-3BCD-40E3-A4F1-619D605B8467
P50
description
researcher ORCID ID = 0000-0002-6617-5976
@en
wetenschapper
@nl
name
Kristoffer Hellstrand
@ast
Kristoffer Hellstrand
@en
Kristoffer Hellstrand
@es
Kristoffer Hellstrand
@nl
type
label
Kristoffer Hellstrand
@ast
Kristoffer Hellstrand
@en
Kristoffer Hellstrand
@es
Kristoffer Hellstrand
@nl
prefLabel
Kristoffer Hellstrand
@ast
Kristoffer Hellstrand
@en
Kristoffer Hellstrand
@es
Kristoffer Hellstrand
@nl
P1006
P214
P1006
P21
P214
P31
P496
0000-0002-6617-5976
P7859
viaf-291521730